Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.
Acta Obstet Gynecol Scand. 2012 Dec;91(12):1415-21. doi: 10.1111/aogs.12014. Epub 2012 Nov 1.
To investigate the duration of effects and health consequences of earlier antenatal corticosteroid exposure in infants born late preterm or term.
Observational cohort study.
Children born after gestational week 34 in Sweden, 1976-1997, whose mothers were hospitalized for imminent preterm delivery. The children were followed to their 11th birthday.
The cohort consisted of 11 873 infants, of whom 8620 were exposed.
Exposure was estimated at hospital level. Infants born at a hospital practicing antenatal corticosteroid administration were classified as exposed. Estimation of hospital routines was based on questionnaire data, telephone interviews with physicians and pharmacy sales, validated in a random sample of medical records. Logistic regression was used to assess associations with adjustments for pregnancy length, birth year and hospital level.
Rates and odds ratios of mortality, respiratory distress syndrome, bronchopulmonary dysplasia, epilepsy, cerebral palsy, childhood diabetes, birthweight, length and head circumference for all infants, and for preterm and term infants, respectively.
Exposed infants had reduced risks of respiratory distress syndrome (odds ratio 0.54, 95% confidence interval 0.35-0.83) and small head circumference (odds ratio 0.47, 95% confidence interval 0.36-0.61), and an increased risk of low Apgar scores (odds ratio 1.40, 95% confidence interval 1.01-1.94), most pronounced in infants born after gestational week 37.
Infants born after gestational week 34 seem to benefit from earlier antenatal corticosteroid administration, with reduced risks of respiratory distress syndrome. However, the treatment was less beneficial for term infants, because they also had increased risk of low Apgar scores.
探讨在晚期早产儿或足月产儿中,早期产前皮质类固醇暴露的持续时间及其对健康的影响。
观察性队列研究。
1976 年至 1997 年,瑞典,母亲因早产即将分娩而住院的妊娠 34 周后出生的儿童。对这些儿童进行了 11 岁生日的随访。
该队列包括 11873 名婴儿,其中 8620 名暴露于产前皮质类固醇。
在医院层面进行暴露评估。在实施产前皮质类固醇治疗的医院出生的婴儿被归类为暴露。医院常规的估计是基于问卷调查数据、医生和药房销售的电话访谈,在医疗记录的随机样本中进行了验证。使用逻辑回归来评估与妊娠时间、出生年份和医院水平调整后的相关性。
所有婴儿以及早产儿和足月产儿的死亡率、呼吸窘迫综合征、支气管肺发育不良、癫痫、脑瘫、儿童糖尿病、出生体重、身长和头围的发生率和比值比。
暴露组婴儿呼吸窘迫综合征(比值比 0.54,95%置信区间 0.35-0.83)和小头围(比值比 0.47,95%置信区间 0.36-0.61)的风险降低,且低 Apgar 评分(比值比 1.40,95%置信区间 1.01-1.94)的风险增加,在妊娠 37 周后出生的婴儿中最为明显。
妊娠 34 周后出生的婴儿似乎从早期产前皮质类固醇治疗中获益,呼吸窘迫综合征的风险降低。然而,这种治疗对足月产儿的益处较小,因为他们的低 Apgar 评分风险也增加了。